放射性碘难治性转移性甲状腺癌患者短期再分化的可行性
本回顾性研究纳入8例放射性碘难治性转移性甲状腺癌患者,给予曲美替尼联合达拉非尼(BRAF突变)或曲美替尼单药(BRAF野生型)治疗10天,以123I显像评估碘摄取。2例BRAF野生型患者成功恢复碘摄取并在放射性碘治疗后甲状腺球蛋白显著下降;延长TKI至21天无额外获益。作者认为10天TKI治疗即可最大程度恢复碘摄取,减少毒性和治疗费用,但需更大前瞻性试验证实。
要点
- 8例放射性碘难治性转移性甲状腺癌患者接受10天TKI治疗,2例BRAF野生型患者成功恢复碘摄取。
- 2例恢复碘摄取者经放射性碘治疗后甲状腺球蛋白显著下降。
- TKI延长至21天未带来额外获益,作者认为10天即可最大程度恢复碘摄取。
核心结论
- 作者认为该先导研究支持临床前发现,即仅10天TKI治疗即可最大程度恢复碘摄取,减少毒性和治疗费用。
- 作者指出更长治疗未提供任何额外获益,需更大前瞻性试验证实这些发现。
研究设计与样本
- 回顾性研究,纳入8例转移性放射性碘难治性甲状腺癌患者。
- BRAF突变患者接受曲美替尼联合达拉非尼治疗,BRAF野生型患者接受曲美替尼单药治疗,疗程10天。
- 以123I显像评估碘摄取;应答者接受高剂量放射性碘治疗,无应答者继续TKI治疗10天。
主要发现
- 2例患者(均为BRAF野生型)成功恢复碘摄取,放射性碘治疗后甲状腺球蛋白显著下降。
- 将TKI治疗延长至21天未带来进一步获益。
临床怎么用
- 原文未据此给出临床推荐。
局限性
- 原文称该研究为先导研究(pilot study),需更大前瞻性试验证实这些发现。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Radioactive iodine-refractory thyroid cancer (TC) has a poor prognosis, and restoring iodine uptake is a major therapeutic goal. Recent studies have used tyrosine kinase inhibitors (TKIs) for 3-6 wk to achieve redifferentiation, but preclinical data suggest that maximal effects occur within 8-12 d. Methods: In this retrospective study, 8 patients with metastatic radioactive iodine-refractory TC received trametinib plus dabrafenib (for BRAF-mutated disease) or trametinib alone (for BRAF wild-type disease) for 10 d. Iodine uptake was assessed by 123I-scintigraphy; responders received high-dose radioactive iodine therapy, and nonresponders continued TKIs for another 10 d. Results: Two patients (both with BRAF wild-type disease) achieved successful iodine uptake restoration with significant thyroglobulin reduction after radioactive iodine therapy. Extending TKI treatment to 21 d did not yield further benefit. Conclusion: Our pilot study supports preclinical findings that maximal restoration of iodine uptake is achieved after only 10 d of TKI therapy, reducing toxicity and treatment costs. Longer treatment did not provide any additional benefit. Larger prospective trials are needed to confirm these findings.
引用
- von Hinten J, Viering O, Bundschuh RA, et al. Feasibility of Short-Term Redifferentiation in Patients with Radioactive Iodine-Refractory Metastatic Thyroid Cancer. J Nucl Med. 2025. PMID: 40473458. doi:10.2967/jnumed.125.270055
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。